[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"egfr-inhibitor-associated-rash\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:egfr-inhibitor-associated-rash":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100579943","phase-1-a-study-to-evaluate-topical-atr04-484-for-egfri-associated-dermal-toxicity-100579943",false,"NCT06830863","A Study to Evaluate Topical ATR04-484 for EGFRi-Associated Dermal Toxicity","A Phase 1\u002F2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety, Bioavailability, and Effect of Topically Administered ATR04-484 for Moderate to Severe EGFRi-Associated Dermal Toxicity","Inclusion Criteria:\n\n* Adults ≥18 years of age\n* Has Grade 2 or 3 non-infected moderate to severe EGFRi-related dermal toxicity affecting the face (the neck, chest, back and other areas may also be affected)\n\nExclusion Criteria:\n\n* Significant skin disease other than EGFRi-related dermal toxicity\n* Treatment with topical mid- to high-potency topical corticosteroids, or topical antibiotics or antibacterial washes on the face, neck, chest, or back within 14 days prior to baseline; treatment with systemic antibiotics or systemic corticosteroids within 14 days prior to baseline\n* Residing with an immunocompromised person residing with them in the same dwelling from the baseline visit through 2 weeks after the treatment period","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The goal of this randomized clinical trial is to learn if topical treatment with ATR04-484 can treat skin rash in patients undergoing EGFR inhibitor (EGFRi) therapy. The primary goal of the study is to determine safety and tolerability of ATR04-484, and the secondary goal of the study is to assess efficacy signals of ATR04-484. Researchers will compare treatment of ATR04-484 to its vehicle. Participants will:\n\n* Apply ATR04-484 or vehicle daily for 28 days\n* Visit the clinic periodically for evaluation and sample collection",[27],"EGFR Inhibitor-associated Rash",[29,30,31,32],"EGFR","acneiform","EGFR inhibitor-associated rash","EGFRi","RECRUITING","2026-02-09",{"date":36,"type":37},"2026-02-11","ACTUAL",{"date":39,"type":37},"2025-08-25",{"date":41,"type":20},"2027-02-15",{"name":43,"class":44},"Azitra Inc.","INDUSTRY",6,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100578958","phase-2-tar-0520-gel-in-egfr-inhibitor-induced-folliculitis-100578958","NCT06818058","TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis","A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.","Inclusion Criteria:\n\n* male or female, who is at least 18 years of age or older at the screening visit\n* patients with clinical diagnosis of metastatic colorectal carcinoma planned to be treated with cetuximab or panitumumab injections as part of the chemotherapy protocol\n* patients who can understand and sign the Informed Consent Form, can communicate with investigator,can understand and comply with requierements of the protocol, and can apply the study gel by himself\u002Fherself or have giver who can apply the product\n* patients with predicted life expectency of \\> 3 months\n* patients willing and able to comply with all of the time commitements and procedural requirements of the clinical trial protocol\n\nExclusion Criteria:\n\n* patients with medical history of EGFR treatment in the past 2 years\n* patients with any underlying physical ,psychological or medical condition that, in the opinion of the invstigator, would make it unlikely that the patient will comply with the protocol or complete the study protocol\n* patients with any uncotrolled or serious disease, or any medical or surgical condition,that may put the subject at significant risk (according to the investigator's judgement) if he\u002Fshe participates in the clinical trial\n* patients with history of other skin disorders (eg.atopic dermatitis,psoriasis,recurrent skin infections), or a history of illness that, in the opinion of the investigator, would confound the results of the study\n* patients with significant skin disease other than EGFRi-induced folliculits within the same body areas planned for study drug application\n* patients with a beard that would interfere with administration of the study drug and assessement of study endpoints\n* patients with active infection within the treatment area ot in other body areas that requieres initiation of systemic antibiotics\n* patients with known or suspected allergies or sensitivities to any components of the study drugs\n* female patients who are pregnant or lactating","80 Years",{"count":55,"type":20},60,[24],"A Phase II, multicentric, randomized, double-blind, placebo-controlled, parallel- group trial to confirm the good safaty profile and to explore the preventive effect of topically applied TAR-0520 gel on folliculitis developed in metastatic colorectal cancer (mCRC) patients treated with monoclonal anti-EGFR antibodies.",[27],[60,61],"EGFR inhibitor-induced skin rash;","EGFR inhibitor-induced folliculitis","2025-02-05",{"date":64,"type":37},"2025-02-10",{"date":66,"type":37},"2025-01-20",{"date":68,"type":20},"2026-09-30",{"name":70,"class":44},"Tarian Pharma",3]